Navigation Links
BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
Date:3/30/2009

xclusivity in the United States and ten years of market exclusivity in the E.U.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. To learn more about PKU, please visit www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin to Present at the 4th Annual Citi Biotech Day
2. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
3. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
4. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
5. BioMarin to Present at the Piper Jaffray Healthcare Conference
6. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces Third Quarter 2008 Financial Results
9. BioMarin Corrects Information Included in Bloomberg Article
10. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
11. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., a ... food processing industry, is asking industry professionals to prepare ... of the E2 soap they’re currently using to the ... . Hand hygiene is critical to fighting cross-contamination ... environment. Six key criteria are identified to evaluate the ...
(Date:8/28/2014)... August 28, 2014 “This kit has an ... screen from 0 to 150 ppb,” said Mark Tess, PhD, ... significant benefit to plant owners and USDA-GIPSA inspection agencies that ... commodities. Testing can take place in a matter of minutes ... the plant test the feed and grain before accepting it, ...
(Date:8/28/2014)... are important devices in spintronics, an electronic which ... electrons but also on their spin and the ... electric into magnetic signals and vice versa. Recently, ... the Institute of Physics at Johannes Gutenberg University ... Prague, and Japan, has for the first time ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3
... Immune Design Corp. (IDC), a privately held biotechnology ... disease, cancer and allergy, announced today that it ... Sanofi-Aventis to investigate the use of IDC,s Glucopyranosyl ... (TLR-4) agonist, in the field of allergy. ...
... 25, 2011 Sangamo BioSciences, Inc. (Nasdaq: SGMO ... For the third quarter ended September 30, ... or $0.18 per share, compared to a net loss of ... in 2010. As of September 30, 2011, the Company had ...
... Graduate Institute (KGI) Research Professor James M. Cregg, PhD, will ... from February 23 – March 3 in Alpbach, Austria. ... development and use of the yeast species, Pichia pastoris ... At the Pichia 2012 Conference he will discuss ...
Cached Biology Technology:Sangamo BioSciences Reports Third Quarter 2011 Financial Results 2Sangamo BioSciences Reports Third Quarter 2011 Financial Results 3Sangamo BioSciences Reports Third Quarter 2011 Financial Results 4Sangamo BioSciences Reports Third Quarter 2011 Financial Results 5Sangamo BioSciences Reports Third Quarter 2011 Financial Results 6KGI Professor Cregg to Be Featured Speaker at Pichia 2012 Conference 2
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and Aging ... UT Health Science Center at San Antonio, have found ... longest-lived rodent, the naked mole rat. , They ... mole rats protects and alters the activity of the ... , The factor also protects proteasome function in human, ...
(Date:8/29/2014)... explored the type and number of connections in transcription ... on robustness in a study published in PLOS ... that the assortativity signature contributes to a network,s resilience ... varying the out-out assortativity of TFN models has a ... other three types of assortativity," said Dov A. Pechenick, ...
(Date:8/29/2014)... - In a cell,s nucleus, chromosomal DNA is ... an amalgam biologists call chromatin. Until about two ... "sidekick," the mere packing material around which the ... have developed a greater appreciation for how DNA/histone ... from multiple research institutions studying the sequence of ...
Breaking Biology News(10 mins):Factor in naked mole rat's cells enhances protein integrity 2Assortativity signatures of transcription factor networks contribute to robustness 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3
... two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), ... myeloid leukemias (AML). As a result, mutant IDH proteins have ... of adult leukemia. Now a scientific team at Beth ... mouse model of the most common IDH2 mutation in human ...
... the latest in the ocean sciences at the 2014 ... Hotel information, U.S. visa regulations for international reporters ... sciences at the 2014 Ocean Sciences Meeting , ... research findings about the world,s ,oceans at the Ocean ...
... early life experiences may affect food choices in adulthood will ... which includes researchers from the Sahlgrenska Academy. The 7.4 ... out what drives decisions of when we eat and the ... the University of Edinburgh, will examine how eating habits develop ...
Cached Biology News:Animal model demonstrates role for metabolic enzyme in acute myeloid leukemia 2Animal model demonstrates role for metabolic enzyme in acute myeloid leukemia 32014 Ocean Sciences Meeting: Discover the latest in oceanography; press registration open 22014 Ocean Sciences Meeting: Discover the latest in oceanography; press registration open 32014 Ocean Sciences Meeting: Discover the latest in oceanography; press registration open 480 million SEK study seeks to explain what drives our appetites 2
... Microarrays designed for proteomic scale kinase ... and drug discovery research built on the ... platform. These microarrays are available as part ... Peptide Microarray Service. Probe Content ...
... (Ruggedized Advanced Pathogen Identification Device) is ... for field hospitals, mobile laboratories and ... its ruggedness, it is designed with ... the LightCycler instrument. By taking advantage ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... as a carrier in nucleic ... form: Solution in 10 mM ... mM EDTA Preparation Note: Phenol-chloroform ... Concentration: 10 mg/mL Physical ...
Biology Products: